StocksMedium•9 November 2026•
1 min read
Ionis Pharmaceuticals Shares Plunge 28% Despite Q3 Earnings Beat
Key Facts
1Ionis Pharmaceuticals exceeded Q3 2026 earnings expectations.
2The company's shares fell 28% following a 50% cut to revenue guidance for a key drug.
Ionis Pharmaceuticals shares fell 28% following a 50% reduction in revenue guidance for a key drug. Investing.com reported that the decline occurred despite the company exceeding earnings expectations for the third quarter of 2026.
The massive guidance cut for a flagship product triggered heavy selling pressure on Ionis Pharmaceuticals stock, as the market prioritized the lowered revenue outlook over the quarterly earnings beat. No updated price levels were available for the instrument during the November 9, 2026 session.